Patent ID: 8629135

Claim:
A method of treating and/or mitigating cancer, comprising administering to a subject gemcitabine and a compound of Formula (1B): where X is sp 2 hybridized carbon, sp 3 hybridized carbon, or sp 3 hybridized nitrogen; Y is sp 2 hybridized carbon bonded to a non-cyclic aliphatic group optionally comprising one or more heteroatoms; R 4 and R 5 are independently H or alkyl; R 6 and R 7 are independently alkyl; Z is independently H, aryl, halo, nitro, hydroxyl, amino, thiol, alkoxyl, amido, amide, carboxyl, alkenyl, allyl, cyano, substituted alkyl, alkylamino, halogenated alkyl, or unsubstituted alkyl; d is 0-7; e is 0-7; m is 0; p is 0-2; q is 1; and dotted line indicates that the compound may be saturated or unsaturated at that location; where the cancer is a cancer associated with expression of REarranged during Transfection protooncogene (“RET”) selected from the group consisting of medullary thyroid carcinoma, papillary thyroid carcinoma, pheochromocytoma, multiple endocrine neoplasia type 2 related tumor, testicular cancer, and pancreatic cancer; and where the amount of compound (1B) administered corresponds to between about 0.02 mg/kg to about 100 mg/kg in the subject.